COVID-19 and systemic anti-cancer therapy

Xichun HU; Zhihuang HU; Biyun WANG; Jialei WANG; Rong TAO; Jian ZHANG; Weijian GUO; Jie CHEN; Zhiguo LUO; Ting LI; Mingzhu HUANG; Lixin QIU; Youzhou SANG

doi:10.19401/j.cnki.1007-3639.2022.06.004

您当前的位置：

首页 >

文章列表页 >

COVID-19 and systemic anti-cancer therapy

Specialists' Commentary | 更新时间：2025-12-31

- COVID-19 and systemic anti-cancer therapy
- China Oncology Vol. 32, Issue 6, Pages: 499-511(2022)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院大内科,复旦大学上海医学院肿瘤学系,上海 200032
  2. 复旦大学附属肿瘤医院胸部肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
  3. 复旦大学附属肿瘤医院乳腺及泌尿肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
  4. 复旦大学附属肿瘤医院淋巴瘤科,复旦大学上海医学院肿瘤学系,上海 200032
  5. 复旦大学附属肿瘤医院Ⅰ期临床试验病房,复旦大学上海医学院肿瘤学系,上海 200032
  6. 复旦大学附属肿瘤医院消化肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
  7. 复旦大学附属肿瘤医院头颈及神经内分泌肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.06.004
  CLC： R730.53
- Received：08 May 2022，
  
  Revised：2022-05-20，
  
  Published：30 June 2022
- 稿件说明：
移动端阅览
Xichun HU, Zhihuang HU, Biyun WANG, et al. COVID-19 and systemic anti-cancer therapy[J]. China Oncology, 2022, 32(6): 499-511.
DOI：

Xichun HU, Zhihuang HU, Biyun WANG, et al. COVID-19 and systemic anti-cancer therapy[J]. China Oncology, 2022, 32(6): 499-511. DOI： 10.19401/j.cnki.1007-3639.2022.06.004.

摘要

新型冠状病毒感染的肺炎（corona virus disease 2019

COVID-19）疫情仍严重影响着世界各国的医疗卫生体系

而恶性肿瘤患者由于较低的免疫功能状态及更多的风险暴露

影响更甚。本文通过检索PubMed数据库中与本研究目的直接相关的国内外相关文献

并参考相关诊治指南

总结了国内外关于恶性肿瘤与COVID-19相关的研究数据

以论述该人群的个体防护、抗肿瘤治疗、合并感染的转归以及患者的临床管理策略。我们发现恶性肿瘤患者感染COVID-19的概率更高

临床预后更差

尤其是肺癌和血液系统肿瘤。全身化疗可能延缓人体对严重急性呼吸综合征冠状病毒2型（severe acute respiratory syndrome corona virus 2

SARS-CoV-2）的清除时间

进而对COVID-19的临床结局产生负面影响

部分内分泌治疗药物、靶向药物对其影响较小

而免疫检查点抑制剂治疗方面的证据尚不够充分。临床工作中

加强肿瘤患者的个体防护、合理调整抗肿瘤治疗方案、优化临床诊治流程具有重要价值。

Abstract

The corona virus disease 2019 (COVID-19) pandemic continues to severely impact healthcare systems around the world

and patients with cancer are even worse affected owing to compromised immune status and greater exposure risk. In the present review

we retrieved the relevant literature including guidelines and consensuses directly related to the purpose of this study from the PubMed database

and then summarized the research data on cancer and COVID-19

aiming to discuss the personal protection

systemic anti-cancer therapy

outcome of co-infection

and the clinical management strategy in this population. We found that patients with malignant tumors had a higher chance of suffering COVID-19

co-infection of whom had an even worse clinical prognosis

especially for those with lung cancer or hematologic cancers. Systemic chemotherapy may delay the clearance of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) virus of human body

and thus have a negative impact on the clinical outcomes of COVID-19

while certain endocrine therapy and targeted drugs having limited or no impact. There has been no sufficient evidence for the impact of immune checkpoint therapy on the outcomes of COVID-19 till now. It is of great value to strengthen the personal protection of patients

adjust the anti-tumor treatments rationally and optimize the clinical management processes.

关键词

Keywords

references

国家卫生健康委员会办公厅 , 国家中医药管理局办公室 . 新型冠状病毒肺炎诊疗方案(试行第九版) [EB/OL ] [2022-04-20 ] http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml , 2022.

General Office of the National Health Commission , Office of the State Administration of Traditional Chinese Medicine . Diagnosis and treatment plan for novel coronavirus pneumonia (trial version 9) [EB/OL ] [2022-04-20 ] . > http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml , 2022.

ZENG C , EVANS J P , REISINGER S , et al . Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients [J ] . Cell Biosci , 2021 , 11 ( 1 ): 197 . DOI: 10.1186/s13578-021-00713-2 http://doi.org/10.1186/s13578-021-00713-2 https://doi.org/10.1186/s13578-021-00713-2 https://doi.org/10.1186/s13578-021-00713-2

PASSAMONTI F , CATTANEO C , ARCAINI L , et al . Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study [J ] . Lancet Haematol , 2020 , 7 ( 10 ): e737-e745.

VAN KAMPEN J J A , VAN DE VIJVER D A M C , FRAAIJ P L A , et al . Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) [J ] . Nat Commun , 2021, 12 ( 1 ): 267 . DOI: 10.1038/s41467-020-20568-4 http://doi.org/10.1038/s41467-020-20568-4 https://doi.org/10.1038/s41467-020-20568-4 https://doi.org/10.1038/s41467-020-20568-4

GOUBET A G , DUBUISSON A , GERAUD A , et al . Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis [J ] . Cell Death Differ , 2021 , 28 ( 12 ): 3297 - 3315 . DOI: 10.1038/s41418-021-00817-9 http://doi.org/10.1038/s41418-021-00817-9 https://doi.org/10.1038/s41418-021-00817-9 https://doi.org/10.1038/s41418-021-00817-9

ROGADO J , GULLÓN P , OBISPO B , et al . Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors [J ] . Eur J Cancer , 2021 , 148 : 58 - 60 . DOI: 10.1016/j.ejca.2021.02.011 http://doi.org/10.1016/j.ejca.2021.02.011 https://linkinghub.elsevier.com/retrieve/pii/S0959804921000940 https://linkinghub.elsevier.com/retrieve/pii/S0959804921000940

BABADY N E , COHEN B , MCCLURE T , et al . Variable duration of viral shedding in cancer patients with coronavirus disease 2019 (COVID-19) [J ] . Infect Control Hosp Epidemiol , 2021 : 1 - 3 .

AYDILLO T , GONZALEZ-REICHE A S , ASLAM S , et al . Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer [J ] . N Engl J Med , 2020 , 383 ( 26 ): 2586 - 2588 . DOI: 10.1056/NEJMc2031670 http://doi.org/10.1056/NEJMc2031670 http://www.nejm.org/doi/10.1056/NEJMc2031670 http://www.nejm.org/doi/10.1056/NEJMc2031670

GOYAL A , CARDOZO-OJEDA E F , SCHIFFER J T . Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response [J ] . Sci Adv , 2020 , 6 ( 47 ): eabc7112.

LIU B , HAN J Y , CHENG X H , et al . Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients [J ] . Sci Rep , 2020 , 10 ( 1 ): 17718 . DOI: 10.1038/s41598-020-73955-8 http://doi.org/10.1038/s41598-020-73955-8 https://doi.org/10.1038/s41598-020-73955-8 https://doi.org/10.1038/s41598-020-73955-8

HAMMOND J , LEISTER-TEBBE H , GARDNER A , et al . Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19 [J ] . N Engl J Med , 2022 , 386 ( 15 ): 1397 - 1408 . DOI: 10.1056/NEJMoa2118542 http://doi.org/10.1056/NEJMoa2118542 http://www.nejm.org/doi/10.1056/NEJMoa2118542 http://www.nejm.org/doi/10.1056/NEJMoa2118542

NCCN . Management of covid-19 infection in patients with cancer [EB/OL ] . https://www.nccn.org/docs/default-source/covid-19/2021-covid-infectious-disease-management.pdf?sfvrs n =63f70c30_7 https://www.nccn.org/docs/default-source/covid-19/2021-covid-infectious-disease-management.pdf?sfvrs n =63f70c30_7 https://www.nccn.org/docs/default-source/covid-19/2021-covid-infectious-disease-management.pdf?sfvrs=63f70c30_7 , 2021.

LIU Y , YAN L M , WAN L G , et al . Viral dynamics in mild and severe cases of COVID-19 [J ] . Lancet Infect Dis , 2020 , 20 ( 6 ): 656 - 657 . DOI: 10.1016/S1473-3099(20)30232-2 http://doi.org/10.1016/S1473-3099(20)30232-2 https://linkinghub.elsevier.com/retrieve/pii/S1473309920302322 https://linkinghub.elsevier.com/retrieve/pii/S1473309920302322

JACOB A S , KAUL H , FUCHS M , et al . Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma [J ] . Infection , 2022 : 1 - 8 .

LIANG W H , GUAN W J , CHEN R C , et al . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China [J ] . Lancet Oncol , 2020 , 21 ( 3 ): 335 - 337 . DOI: 10.1016/S1470-2045(20)30096-6 http://doi.org/10.1016/S1470-2045(20)30096-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204520300966 https://linkinghub.elsevier.com/retrieve/pii/S1470204520300966

AYHAN M , LAÇIN Ş , ÖZYÜKSELER D T , et al . Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? [J ] . J Oncol Pharm Pract , 2021 , 27 ( 6 ): 1461 - 1467 . DOI: 10.1177/10781552211015762 http://doi.org/10.1177/10781552211015762 http://journals.sagepub.com/doi/10.1177/10781552211015762 http://journals.sagepub.com/doi/10.1177/10781552211015762

JEE J , FOOTE M B , LUMISH M , et al . Chemotherapy and COVID-19 outcomes in patients with cancer [J ] . J Clin Oncol , 2020 , 38 ( 30 ): 3538 - 3546 . DOI: 10.1200/JCO.20.01307 http://doi.org/10.1200/JCO.20.01307 https://ascopubs.org/doi/10.1200/JCO.20.01307 https://ascopubs.org/doi/10.1200/JCO.20.01307

LEE A J X , PURSHOUSE K . COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic [J ] . Br J Cancer , 2021 , 124 ( 11 ): 1777 - 1784 . DOI: 10.1038/s41416-021-01324-x http://doi.org/10.1038/s41416-021-01324-x https://doi.org/10.1038/s41416-021-01324-x https://doi.org/10.1038/s41416-021-01324-x

COELHO D B , SANTOS V , ARAÚJO D , et al . Management of coronavirus disease 2019 patients with lung cancer: experience from a thoracic oncology center [J ] . Front Mol Biosci , 2021, 8 : 639676 . DOI: 10.3389/fmolb.2021.639676 http://doi.org/10.3389/fmolb.2021.639676 https://www.frontiersin.org/articles/10.3389/fmolb.2021.639676/full https://www.frontiersin.org/articles/10.3389/fmolb.2021.639676/full

SUTANDYO N , JAYUSMAN A M , WIDJAJA L , et al . Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as mortality predictor of advanced stage non-small cell lung cancer (NSCLC) with COVID-19 in Indonesia [J ] . Eur Rev Med Pharmacol Sci , 2021 , 25 ( 10 ): 3868 - 3878 .

LUO J , RIZVI H , PREESHAGUL I R , et al . COVID-19 in patients with lung cancer [J ] . Ann Oncol , 2020 , 31 ( 10 ): 1386 - 1396 . DOI: 10.1016/j.annonc.2020.06.007 http://doi.org/10.1016/j.annonc.2020.06.007 https://linkinghub.elsevier.com/retrieve/pii/S092375342039894X https://linkinghub.elsevier.com/retrieve/pii/S092375342039894X

PASSARO A , BESTVINA C , VELEZ VELEZ M , et al . Severity of COVID-19 in patients with lung cancer: evidence and challenges [J ] . J Immunother Cancer , 2021 , 9 ( 3 ): e002266.

VÁRNAI C , PALLES C , ARNOLD R , et al . Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19 [J ] . JAMA Netw Open , 2022 , 5 ( 2 ): e220130.

GARASSINO M C , WHISENANT J G , HUANG L C , et al . COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study [J ] . Lancet Oncol , 2020 , 21 ( 7 ): 914 - 922 . DOI: 10.1016/S1470-2045(20)30314-4 http://doi.org/10.1016/S1470-2045(20)30314-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303144 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303144

PROVENCIO M , MAZARICO GALLEGO J M , CALLES A , et al . Lung cancer patients with COVID-19 in Spain: GRAVID study [J ] . Lung Cancer , 2021 , 157 : 109 - 115 . DOI: 10.1016/j.lungcan.2021.05.014 http://doi.org/10.1016/j.lungcan.2021.05.014 https://linkinghub.elsevier.com/retrieve/pii/S0169500221001938 https://linkinghub.elsevier.com/retrieve/pii/S0169500221001938

HAINEALA B , ZGURA A , BADIU D C , et al . Lung cancer, covid-19 infections and chemotherapy [J ] . In Vivo , 2021 , 35 ( 3 ): 1877 - 1880 . DOI: 10.21873/invivo.12450 http://doi.org/10.21873/invivo.12450 http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.12450 http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.12450

TRIFANESCU O G , GALES L , BACINSCHI X , et al . Impact of the COVID-19 pandemic on treatment and oncologic outcomes for cancer patients in Romania [J ] . In Vivo , 2022 , 36 ( 2 ): 934 - 941 . DOI: 10.21873/invivo.12783 http://doi.org/10.21873/invivo.12783 http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.12783 http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.12783

WU Q , LUO S M , XIE X H . The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: A meta-analysis based on 52 cohorts incorporating 9 231 participants [J ] . BMC Cancer , 2022 , 22 ( 1 ): 241 . DOI: 10.1186/s12885-022-09320-x http://doi.org/10.1186/s12885-022-09320-x https://doi.org/10.1186/s12885-022-09320-x https://doi.org/10.1186/s12885-022-09320-x

HERMEL D J , CHAM J , SPIERLING BAGSIC S R , et al . An observational study of hospitalized COVID-19 patients with cancer in San Diego County [J ] . Future Oncol , 2022 , 18 ( 6 ): 719 - 725 . DOI: 10.2217/fon-2021-1116 http://doi.org/10.2217/fon-2021-1116 https://www.futuremedicine.com/doi/10.2217/fon-2021-1116 https://www.futuremedicine.com/doi/10.2217/fon-2021-1116

YANG K Y , SHENG Y H , HUANG C L , et al . Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study [J ] . Lancet Oncol , 2020 , 21 ( 7 ): 904 - 913 . DOI: 10.1016/S1470-2045(20)30310-7 http://doi.org/10.1016/S1470-2045(20)30310-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303107 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303107

MANDALA M , LORIGAN P , DE LUCA M , et al . SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study [J ] . J Immunother Cancer , 2021 , 9 ( 2 ): e001694.

PASSARO A , ADDEO A , VON GARNIER C , et al . ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer [J ] . ESMO Open , 2020 , 5 ( Suppl 3 ): e000820.

SO M , KABATA H , FUKUNAGA K , et al . Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis [J ] . BMC Pulm Med , 2021 , 21 ( 1 ): 97 . DOI: 10.1186/s12890-021-01463-0 http://doi.org/10.1186/s12890-021-01463-0 https://doi.org/10.1186/s12890-021-01463-0 https://doi.org/10.1186/s12890-021-01463-0

PINATO D J , ZAMBELLI A , AGUILAR-COMPANY J , et al . Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients [J ] . Cancer Discov , 2020 : CD-20-0773.

VUAGNAT P , FRELAUT M , RAMTOHUL T , et al . COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area [J ] . Breast Cancer Res , 2020 , 22 ( 1 ): 55 . DOI: 10.1186/s13058-020-01293-8 http://doi.org/10.1186/s13058-020-01293-8 https://doi.org/10.1186/s13058-020-01293-8 https://doi.org/10.1186/s13058-020-01293-8

WEI J L , WU M J , LIU J , et al . Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China [J ] . Breast , 2021 , 59 : 102 - 109 . DOI: 10.1016/j.breast.2021.06.006 http://doi.org/10.1016/j.breast.2021.06.006 https://linkinghub.elsevier.com/retrieve/pii/S096097762100401X https://linkinghub.elsevier.com/retrieve/pii/S096097762100401X

ZHOU Y D , HOU Y , SHEN J Y , et al . Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 [J ] . Cell Discov , 2020 , 6 : 14 . DOI: 10.1038/s41421-020-0153-3 http://doi.org/10.1038/s41421-020-0153-3 https://doi.org/10.1038/s41421-020-0153-3 https://doi.org/10.1038/s41421-020-0153-3

MARTIN W R , CHENG F X . Repurposing of FDA-approved toremifene to treat COVID-19 by blocking the spike glycoprotein and NSP14 of SARS-CoV-2 [J ] . J Proteome Res , 2020 , 19 ( 11 ): 4670 - 4677 . DOI: 10.1021/acs.jproteome.0c00397 http://doi.org/10.1021/acs.jproteome.0c00397 https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00397 https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00397

ZU S L , LUO D , LI L L , et al . Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 435 . DOI: 10.1038/s41392-021-00853-4 http://doi.org/10.1038/s41392-021-00853-4 https://doi.org/10.1038/s41392-021-00853-4 https://doi.org/10.1038/s41392-021-00853-4

HU S Y , YIN F Y , NIE L T , et al . Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer [J ] . Front Endocrinol (Lausanne ), 2022 , 13 : 829879 . DOI: 10.3389/fendo.2022.829879 http://doi.org/10.3389/fendo.2022.829879 https://www.frontiersin.org/articles/10.3389/fendo.2022.829879/full https://www.frontiersin.org/articles/10.3389/fendo.2022.829879/full

OTTAVIANO M , CURVIETTO M , RESCIGNO P , et al . Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists [J ] . J Immunother Cancer , 2020 , 8 ( 2 ): e001154.

Recommendations for prioritization , treatment and triage of breast cancer patients during the covid-19 pandemic ［EB/OL］.American College of Surgeons Available at https://www.facs.org/qualityprograms/cancer/executive-summary https://www.facs.org/qualityprograms/cancer/executive-summary https://www.facs.org/qualityprograms/cancer/executive-summary . Accessed March 26, 2020.

DE AZAMBUJA E , TRAPANI D , LOIBL S , et al . ESMO Management and treatment adapted recommendations in the COVID-19 era: breast cancer [J ] . ESMO Open , 2020 , 5 ( Suppl 3 ): e000793.

PINATO D J , TABERNERO J , BOWER M , et al . Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study [J ] . Lancet Oncol , 2021 , 22 ( 12 ): 1669 - 1680 . DOI: 10.1016/S1470-2045(21)00573-8 http://doi.org/10.1016/S1470-2045(21)00573-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204521005738 https://linkinghub.elsevier.com/retrieve/pii/S1470204521005738

ZHANG H Y , WANG L W , CHEN Y Y , et al . Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China [J ] . Cancer , 2020, 126 ( 17 ): 4023 - 4031 . DOI: 10.1002/cncr.33042 http://doi.org/10.1002/cncr.33042 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33042 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33042

LEE L Y W , CAZIER J B , STARKEY T , et al . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1309 - 1316 . DOI: 10.1016/S1470-2045(20)30442-3 http://doi.org/10.1016/S1470-2045(20)30442-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304423 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304423

LIU H Q , YANG D , CHEN X Y , et al . The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis [J ] . Cancer Med , 2021 , 10 ( 3 ): 1043 - 1056 . DOI: 10.1002/cam4.3692 http://doi.org/10.1002/cam4.3692 https://onlinelibrary.wiley.com/doi/10.1002/cam4.3692 https://onlinelibrary.wiley.com/doi/10.1002/cam4.3692

VÁRNAI C , PALLES C , ARNOLD R , et al . Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19 [J ] . JAMA Netw Open , 2022 , 5 ( 2 ): e220130.

MUKHERJI R , MARSHALL J L . Lessons learned in managing patients with colorectal cancer during the COVID-19 pandemic [J ] . Curr Treat Options Oncol , 2021 , 22 ( 10 ): 93 . DOI: 10.1007/s11864-021-00888-3 http://doi.org/10.1007/s11864-021-00888-3 https://doi.org/10.1007/s11864-021-00888-3 https://doi.org/10.1007/s11864-021-00888-3

GARCÍA-SUÁREZ J , DE LA CRUZ J , CEDILLO Á , et al . Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 133 . DOI: 10.1186/s13045-020-00970-7 http://doi.org/10.1186/s13045-020-00970-7 https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00970-7 https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00970-7

DULÉRY R , LAMURE S , DELORD M , et al . Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy [J ] . Am J Hematol , 2021 , 96 ( 8 ): 934 - 944 . DOI: 10.1002/ajh.26209 http://doi.org/10.1002/ajh.26209 https://onlinelibrary.wiley.com/doi/10.1002/ajh.26209 https://onlinelibrary.wiley.com/doi/10.1002/ajh.26209

GHIONE P , GU J J , ATTWOOD K , et al . Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies [J ] . Blood , 2021 , 138 ( 9 ): 811 - 814 .

TREON S P , CASTILLO J J , SKARBNIK A P , et al . he BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020; 135(21): 1912-1915 [J ] . Blood , 2021, 137 ( 11 ): 1561 . DOI: 10.1182/blood.2021010938 http://doi.org/10.1182/blood.2021010938 https://ashpublications.org/blood/article/137/11/1561/475497/Treon-SP-Castillo-JJ-Skarbnik-AP-et-al-The-BTK https://ashpublications.org/blood/article/137/11/1561/475497/Treon-SP-Castillo-JJ-Skarbnik-AP-et-al-The-BTK

SCARFÒ L , CHATZIKONSTANTINOU T , RIGOLIN G M , et al . COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus [J ] . Leukemia , 2020 , 34 ( 9 ): 2354 - 2363 . DOI: 10.1038/s41375-020-0959-x http://doi.org/10.1038/s41375-020-0959-x https://doi.org/10.1038/s41375-020-0959-x https://doi.org/10.1038/s41375-020-0959-x

GIESEN N , SPRUTE R , RÜTHRICH M , et al . 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy [J ] . Eur J Cancer , 2021, 147 : 154 - 160 . DOI: 10.1016/j.ejca.2021.01.033 http://doi.org/10.1016/j.ejca.2021.01.033 https://linkinghub.elsevier.com/retrieve/pii/S095980492100054X https://linkinghub.elsevier.com/retrieve/pii/S095980492100054X

LEE L Y , CAZIER J B , ANGELIS V , et al . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study [J ] . Lancet , 2020 , 395 ( 10241 ): 1919 - 1926 . DOI: 10.1016/S0140-6736(20)31173-9 http://doi.org/10.1016/S0140-6736(20)31173-9 https://linkinghub.elsevier.com/retrieve/pii/S0140673620311739 https://linkinghub.elsevier.com/retrieve/pii/S0140673620311739

KUDERER N M , CHOUEIRI T K , SHAH D P , et al . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study [J ] . Lancet , 2020 , 395 ( 10241 ): 1907 - 1918 . DOI: 10.1016/S0140-6736(20)31187-9 http://doi.org/10.1016/S0140-6736(20)31187-9 https://linkinghub.elsevier.com/retrieve/pii/S0140673620311879 https://linkinghub.elsevier.com/retrieve/pii/S0140673620311879

SATHIAN B , ASIM M , BANERJEE I , et al . Impact of COVID-19 on clinical trials and clinical research: a systematic review [J ] . Nepal J Epidemiol , 2020 , 10 ( 3 ): 878 - 887 . DOI: 10.3126/nje.v10i3.31622 http://doi.org/10.3126/nje.v10i3.31622 https://www.nepjol.info/index.php/NJE/article/view/31622 https://www.nepjol.info/index.php/NJE/article/view/31622

DE PAULA B H R , ARAÚJO I , BANDEIRA L , et al . Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic [J ] . Lancet Oncol , 2020 , 21 ( 5 ): 624 - 627 . DOI: 10.1016/S1470-2045(20)30226-6 http://doi.org/10.1016/S1470-2045(20)30226-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204520302266 https://linkinghub.elsevier.com/retrieve/pii/S1470204520302266

李丹 , 刘晓红 , 卢冬青 , 等 . 新型冠状病毒肺炎疫情下抗肿瘤药物临床试验受试者的随访分析 [J ] . 中国新药杂志 , 2021 , 30 ( 12 ): 1099 - 1102 .

LI D , LIU X H , LU D Q , et al . Analysis of follow-up for subjects of anti-cancer clinical trials under COVID-19 [J ] . Chin J New Drugs , 2021 , 30 ( 12 ): 1099 - 1102 .

刘小保 , 高素彬 , 衡建福 , 等 . 新冠肺炎疫情下抗肿瘤药物临床试验现状与紧急应对策略 [J ] . 肿瘤药学 , 2020 , 10 ( S1 ): 2 - 10 .

LIU X B , GAO S B , HENG J F , et al . The Current situation of anti-cancer drug clinical trial during the epidemic of COVID-19 and the emergency response strategies [J ] . Anti Tumor Pharm , 2020 , 10 ( S1 ): 2 - 10 .

刘丹 , 曾圣雅 , 邓璠 , 等 . 临床科研项目知情同意过程存在问题及解决途径 [J ] . 中国医学伦理学 , 2018 , 31 ( 6 ): 732 - 735 .

LIU D , ZENG S Y , DENG F , et al . Existing problems and solution of informed consent in clinical research [J ] . Chin Med Ethics , 2018 , 31 ( 6 ): 732 - 735 .

Views

2619

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer

A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer

The progress of treatment for brain metastases of triple-negative breast cancer

Related Author

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Association Committee of Cancer Pain Fujian Anti-Cancer

Sumei FAN

Congling XIN

Laifang ZHU

Chang LIU

Rui XU

Zhengrong ZHOU

Related Institution

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰